Topamax Draws FDA Warning Letter For Promoting Unsafe Use In Children
Executive Summary
FDA is citing Johnson & Johnson's Topamax for a website and sales aid that lack sufficient safety information
You may also be interested in...
FDA Drug Ad Warning Letters Total Four In September; J&J Cited Three Times
FDA's drug ad division posted four warning letters to its website in the second half of September, three for Johnson & Johnson ads
FDA Drug Ad Warning Letters Total Four In September; J&J Cited Three Times
FDA's drug ad division posted four warning letters to its website in the second half of September, three for Johnson & Johnson ads
FDA Cites J&J Duragesic Promotion For Using Post-Market Abuse Data
FDA has issued a warning letter to Janssen for a Duragesic promotion containing comparative data versus other pain agents on post-marketing reports of abuse